Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen

Nadège Calmels¹, Hervé Seznec¹,₅, Pascal Villa², Laurence Reutenauer¹, Marcel Hibert²,₃, Jacques Haiech²,₃, Pierre Rustin⁴, Michel Koenig¹ and Hélène Puccio*¹

Address: ¹IGBMC (Institut de Généétique et de Biologie Moléculaire et Cellulaire), CNRS/INSERM/Université Louis Pasteur, 67404 Illkirch cedex, France, ²IFR 85/PCBIS (Plateforme de Chimie Biologique Intégrative de Strasbourg), ESBS Pôle APL, 67401 Illkirch, France, ³UMR7175/CNRS/Université Louis Pasteur, 67404 Illkirch cedex, France, ⁴INSERM U676, Hôpital Robert Debré, 75019 Paris, France and ⁵Interface Physique Biologie, Centre d’Etudes Nucléaires de Bordeaux-Gradignan, CNRS/IN2P3-UMR5797, BP120 33175 Gradignan, France

Email: Nadège Calmels - na.dege.calmels@chru-strasbourg.fr; Hervé Seznec - seznech@cenbg.in2p3.fr; Pascal Villa - pascal.villa@pharma.u-strasbg.fr; Laurence Reutenauer - Laurence.Reutenauer@titus.u-strasbg.fr; Marcel Hibert - mhibert@aspirine.u-strasbg.fr; Jacques Haiech - haiech@aspirine.u-strasbg.fr; Pierre Rustin - rustin@rdebre.inserm.fr; Michel Koenig - mkoenig@titus.u-strasbg.fr; Hélène Puccio* - hpuccio@igbmc.u-strasbg.fr

* Corresponding author

Abstract

Background: Pharmacological high-throughput screening (HTS) represents a powerful strategy for drug discovery in genetic diseases, particularly when the full spectrum of pathological dysfunctions remains unclear, such as in Friedreich ataxia (FRDA). FRDA, the most common recessive ataxia, results from a generalized deficiency of mitochondrial and cytosolic iron-sulfur cluster (ISC) proteins activity, due to a partial loss of frataxin function, a mitochondrial protein proposed to function as an iron-chaperone for ISC biosynthesis. In the absence of measurable catalytic function for frataxin, a cell-based assay is required for HTS assay.

Methods: Using a targeted ribozyme strategy in murine fibroblasts, we have developed a cellular model with strongly reduced levels of frataxin. We have used this model to screen the Prestwick Chemical Library, a collection of one thousand off-patent drugs, for potential molecules for FRDA.

Results: The frataxin deficient cell lines exhibit a proliferation defect, associated with an ISC enzyme deficit. Using the growth defect as end-point criteria, we screened the Prestwick Chemical Library. However no molecule presented a significant and reproducible effect on the proliferation rate of frataxin deficient cells. Moreover over numerous passages, the antisense ribozyme fibroblast cell lines revealed an increase in frataxin residual level associated with the normalization of ISC enzyme activities. However, the ribozyme cell lines and FRDA patient cells presented an increase in Mthfd2 transcript, a mitochondrial enzyme that was previously shown to be upregulated at very early stages of the pathogenesis in the cardiac mouse model.

Conclusion: Although no active hit has been identified, the present study demonstrates the feasibility of using a cell-based approach to HTS for FRDA. Furthermore, it highlights the difficulty in the development of a stable frataxin-deficient cell model, an essential condition for productive HTS in the future.

Published: 24 August 2009

BMC Neurology 2009, 9:46 doi:10.1186/1471-2377-9-46

Received: 31 October 2008 Accepted: 24 August 2009

This article is available from: http://www.biomedcentral.com/1471-2377/9/46

© 2009 Calmels et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

In the past 20 years, many genes involved in different rare genetic disorders have been identified. However, many causative genes encode proteins of unknown or partially known function, and with no predictable catalytic sites enabling in vitro drug-target modeling. This makes drug design and identification a difficult task for these orphan diseases. However, new strategies based on automated techniques for high-throughput screening (HTS) have been developed, enabling cell-based assays to identify drug-candidates.

Friedreich's ataxia (FRDA), the most common autosomal recessive ataxia associating spinocerebellar ataxia and cardiomyopathy [1,2], is most often due to a (GAA)ₙ repeat expansion within the first intron of the gene encoding the mitochondrial protein frataxin [3,4]. This frequent mutation leads to a severely reduced level of frataxin as a consequence of transcriptional silencing either through heterochromatin formation or through the formation of a triplex helix [5-7]. Although much progress has been made in understanding the physiopathology of FRDA, the exact role of the frataxin protein is still unclear. Early studies showed iron deposits in cardiac tissue of FRDA patients [8] and in the yeast strain deleted for frataxin (ΔYFH1) thereby linking impaired iron homeostasis to the disease [9]. This led to the hypothesis that elevated levels of mitochondrial iron, as a consequence of frataxin deficiency, could generate cell-damaging superoxide and hydroxyl radicals through Fenton reaction. In support of this, several studies have suggested an increased levels of oxidative stress in patients [10-13], as well as an increased sensitivity to oxidative stress in FRDA patients cells or ΔYFH1-yeast model [14-18]. However, more recent studies have found no evidence of increased oxidative damage in FRDA patients [19-21]. Moreover, experimental data from the conditional FRDA mouse models demonstrated that an increased superfoside production could not explain by itself the FRDA pathology [22] and that the mitochondrial iron accumulation is a late event in the disease [23]. In different mouse and cellular models, the primary biochemical event is the impaired function of iron-sulfur cluster (ISC) proteins such as the aconitases and respiratory chain complexes I-III [23-26]. The role of frataxin as a mitochondrial iron-chaperone for ISC biogenesis is now widely accepted. In addition to severe alteration of mitochondrial and extramitochondrial ISC proteins in frataxin-deficient yeast, mice or human cells [23,27-30], reconstitution and in vivo studies demonstrate that the yeast frataxin homolog Yfh1 is required, although not essential, for ISC biosynthesis [27,29]. Furthermore, frataxin has been demonstrated to interact with the ISC biosynthesis scaffold complex IscU/Nfs1/ISD11 [31-35].

Several therapeutic strategies for FRDA have been developed based on the potential implication of these different pathways in the pathogenesis. Some pharmacological compounds such as antioxidants ([36] for review) or iron chelators [37-39] have shown promise in improving some of the symptoms of the disease. Recently, new therapeutic strategies have been developed to address the frataxin deficiency itself: pharmacological compounds increasing frataxin protein levels (such as recombinant human erythropoietin) or reversing frataxin gene silencing (such as histone deacetylase inhibitors) have been successfully tested in clinical or preclinical trials [40,41]. However there is currently no effective pharmacological treatment available that would slow down the neurological progression of the disease in affected FRDA patients.

The development of a cellular model which reproduces accurately the major aspects of the pathogenesis is the preliminary condition before being able to make a pharmacological screen. To date, there is no appropriate mammalian cell model for FRDA. Indeed, no easily available patient’s tissue or cell lines spontaneously express the generalized ISC enzyme deficiency, and exogenous stress conditions have to be used in order to reveal a differential phenotype with control fibroblasts [14,17,18,42]. Moreover, the reproducibility and relevance of the results obtained with such systems has been contested [10]. More recently, RNA interference strategies have been developed to reproduce frataxin deficiency in mammalian cell lines [16,25,43-47]. Both transient and stable frataxin silencing to undetectable levels in HeLa cells lead to significant reduction of cell growth and activities of ISC proteins [45,47]. Although it seems evident that transient frataxin silencing is not suitable for HTS experiments, it is unclear whether the stable frataxin silencing clone in HeLa cells is an appropriate model for HTS experiments as the clone is reported to have roundish and grainy cells that easily detached from the plate [47]. The RNAi models have been studied to unravel consequences of frataxin deficiency, but no HTS on a FRDA cell-model has yet been published.

In this study, we have developed and characterized a cellular model with partial frataxin deficiency using targeted ribozyme strategy. This model displayed a specific ISC deficit, faithfully and spontaneously reproducing a key feature of the human disease. The growth delay of the frataxin-deficient clone was used as a quantifiable parameter to screen the Prestwick Chemical Library for potential drug-candidates. However, the absence of confirmed active hit and the instability of the cellular model illustrate the difficulty to identify drug-candidates in a small compound library and in accurately replicating the FRDA pathogenesis in a long-term controlled cellular model.

Methods

Ribozyme construction

The pZeoFxR2, pZeoFxR2m and pZeoFxR5 vectors were constructed using the pZeoU1EcoSpe vector [48,49].
Complementary oligonucleotides that encode the antisense sequence, including the 24 highly conserved nucleotides of hammerhead ribozymes (underlined in the sequences below) flanked by 24 and 15 nucleotides of murine frataxin sequence in exon 2 for R2, and by 19 and 20 nucleotides of murine frataxin sequence in 3'-UTR at the end of exon 5 for R5, were synthesized and annealed at 42 °C. The sequences of the oligonucleotides were as follows: R2: 5'-AAT TCC TGA AAT GCA CCA CGC AGA CTG ATG AGT CCG TGA GGA CGA AAC GCT CTG CT TTT GAT-3' and 5'-CTA GAT CAA AAA GCA GAG CGT TTC GTC CTC ACG CAC GGA CTC ATC AGT CTG CCT CAT TTG AGG-3' (sense and antisense, respectively); R5: 5'-AAT TAG GAG CAG GTA TGG GAA GGC AGA ATG ACT CGG TCA AAT GCA GAA CCG TGA ATG TIT CCT CTT CAC GGA CTC ATC AGT CTG CCT CAT ACC TGC TCG TCC T-3' (sense and antisense, respectively). For the mutated ribozyme R2m, the sequences of the oligonucleotides were as follows: R2m: 5'-AAT TCC TCA AAT GCA AAA CGC AGA ATG AGT CCG TGA GGA CGA AAC GCT ATC ATT TTT GAT-3' and 5'-CTA GAT CAA AAA TAA GAG CGT TTC GTC CTC ACG GAC TCA TCA GCC TGC GTG ATT TGG CAT TGT AGG-3' (sense and antisense, respectively), which include four mismatches in the two frataxin complementary sequences of exon 2 (bold in the primer sequences). The resulting duplexes were ligated into the EcoRI and SpeI sites of pZeoU1[EcoSpe] to create pZeoFxnR2 and pZeoFxnR2m. All ligation junctions were sequenced to verify the identity and orientation of the insert.

**Stable transfection of FrdaL2/L- cells**

Murine fibroblast cell lines derived from mice carrying the wild type (Frda+/+), conditional (FrdaL1/3) or compound heterozygous for the deleted and conditional (FrdaL3/L-) frataxin alleles [23] were established using the primary-embryonic technique [50], and then immortalized by transfection with a Large Antigen T construct [51] using the Fugene 6 Transfection Reagent kit (Roche, Indianapolis, Indiana), according to the manufacturer’s protocol. As the mice also expressed an inducible recombinase (Cre-ER[T2] [52], the deletion of the neomycin resistance cassette was approved by the Food and Drug Administration (FDA) and then immortalized by transfection with a Large Antigen T construct [51] using the Fugene 6 Transfection Reagent kit (Roche, Indianapolis, Indiana), according to the manufacturer’s protocol. As the mice also expressed an inducible recombinase (Cre-ER[T2] [52], the deletion of the neomycin resistance cassette was obtained by tamoxifen treatment. The resulting cell line will be noted FrdaL2+/L- in the text.

FrdaL2+/L- immortalized cells were transfected with linearized pZeoFxnR2 or pZeoFxnR2m. Stably transfected fibroblasts were grown in DMEM media (Sigma, Saint Louis, Missouri) with 10% fetal calf serum and 50 μg/ml gancyclovir, supplemented with 250 μg/ml Zeocin (InvivoGen, San Diego, California). Zeocin selection was maintained one month. Monoclonal cell lines were obtained by dilution cloning. Aliquots of the cell line were frozen for cryopreservation in liquid nitrogen, and a new aliquot was used for each screening experiment.

**Genotyping and immunoblot analysis**

Genotyping and DNA analysis were performed as previously described [23]. Immunoblot analysis using the anti-frataxin antibody (R1250 purified sera, 1/1,000) were performed as previously described [22,23]. Briefly, for protein extract, fibroblast cell lines were lysed in a buffer containing 50 mM Tris-HCl pH 7.8, 10% (v/v) glycerol, 1 mM EDTA, 5 mM KCl with protease inhibitor (complete, EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland)). Cell lysates were sonicated and conserved at -20 °C.

**Quantitative RT-PCR (Q-RT-PCR)**

Expression levels of murine genes (Fxn, Mthfd2, Hprt) were determined by Q-RT-PCR as previously described [22,23]. The following primers were used for amplification of human methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and 18S ribosome in the same conditions: MTHFD2, forward 5'-TGA AGA GCG AGA AGT GCT GA-3', reverse 5'-GAA TGC TCC CTG GTG AGG TA-3'; 18S, forward, 5'-CGC GAG TAG AGG TAA TTA-3', reverse 5'-CTG TCG CTC TGG TTC CTT-3'.

**Measurement of cell proliferation rates**

Fibroblasts were plated in 6-well plates at day 1. After cell detachment using trypsin, cell densities were determined daily by visual counting with a hemocytometer. Four counts were performed per well.

**Biochemical analyses**

Cells were harvested in PBS and dry pellet was immediately frozen in liquid nitrogen. The activities of the respiratory chain enzyme complexes succinate cytochrome c reductase (SCCR), cytochrome c oxidase (COX), the mitochondrial and cytosolic aconitases (Aco) and the isocitrate dehydrogenase (IDH) as internal standard were measured spectrophotometrically as previously described [23,53].

**Miniaturization and screening**

The Prestwick Chemical Library (Illkirch, France) which consists of 1120 drugs and bioactive natural compounds approved by the Food and Drug Administration (FDA) was screened on both R2C1 and R2m cell lines in 96-well format. Chemical compounds (~5 mM) dissolved in dimethyl sulfoxide (DMSO) were stored at -20°C into 96 well plates. Just before treatment, compounds were diluted with cell culture medium (DMEM media with 10% fetal calf serum and 50 μg/ml gentamycin) into 96 well plates.

Fresh R2C1 and R2m cell aliquots were thawed for each screening experiment. At the time of passage, R2C1 and R2m cell suspensions were prepared in order to be seeded into 96-well plates (Greiner Bio-one, France, ref 655090).
using a Biomek 2000 Laboratory Automation Workstation (Beckman Coulter inc) (100 µl/well, 10,000 cells/ml).

After sedimentation for 30 minutes, test compounds were added to the wells (100 µl per well, one compound per well) to result in a final concentration of 25 µM. Vehicle control wells contained 0.5% DMSO alone (columns 1 and 12 of each plate). At this DMSO concentration we did not detect any side effect on cells.

Cell proliferation was assessed 72 hours after cell treatment using the commercial CellTiter-Glo Luminescent Cell viability assay (Promega, Madison, WI) generating a luminescent signal directly proportional to the amount of ATP present in metabolically active cells. After incubation, 100 µl of medium was removed and replaced by 100 µl of Promega CellTiter-Glo reagent to each well using the Biomek 2000 workstation. Plates were shaken for 5 min on a plate shaker before reading luminescence on a Victor³ plate reader (PerkinElmer, Norwalk, CT). Luminescence in each treated well was compared to the mean signal obtain in non-treated wells (columns 1 and 12). Positive hits were designated for any compounds with luminescent signal over three standard deviations when compared to untreated control wells. Luminescent ratio between the R2m and R2C1 cell lines was also calculated to check the reproducibility of proliferation delay in the frataxin deficient clone during the experiments (when calculated for non treated cells) and to check the specificity of drug action (when calculated for treated cells).

Results
Partial loss of frataxin leads to a proliferation defect in frataxin ribozyme cell lines
To generate viable FRDA cellular models with reduced frataxin level, we used a ribozyme antisense strategy in cells derived from mice carrying the conditional allele [23]. Two ribozymes, one targeted against exon 2 of the murine frataxin mRNA and one against the 3′-UTR (exon 5), were constructed in the U1snRNA based ribozyme vector pZeoSV [49]. Immortalized compound heterozygous FrdaL2+/L- cells were transfected with either a frataxin-specific ribozyme (pZeoFxnR2 or pZeoFxnR5) or a control construct bearing mutant frataxin sequences (pZeoFxnR2m). The transfected cell lines were subsequently brought through the identical selection process to generate polyclonal and monoclonal colonies of stable transfectants. Two clones were obtained with pZeoFxnR2 (R2C1 and R2C2) and four with pZeoFxnR5 (R5C1 to R5C4). The amount of frataxin was assayed by Q-RT-PCR and western blot. A better frataxin knockdown was obtained with the pZeoFxnR2 clones compared to the R5 clones (Fig. 1B). Clones transfected with mutant-pZeoFxnR2m showed no significant difference compared to non-transfected FrdaL2+/L- cells (data not shown). For subsequent experiments, we selected the two R2 clones (R2C1 and R2C2) which presented significant decrease in frataxin mRNA and protein expression levels (frataxin residual protein level: 9.4% ± 6.1 (p < 0.001) and 18.0% ± 8.4 (p < 0.001), respectively; frataxin mRNA level: 16.5% ± 4.7 (p < 0.001) and 24.9% ± 4.0 (p < 0.001), respectively) (Fig. 1B).

The frataxin deficient clones R2C1 and R2C2 consisted of a homogeneous cell population with no gross morphological phenotype or cell death. Electron microscopy analyses confirmed the absence of morphological phenotype, with normal mitochondria having clear thin cristae and no iron deposits (data not shown). However, growth analysis uncovered a clear proliferation defect in both frataxin deficient clones (Fig. 2). Indeed, the two clones (R2C1 and R2C2) grew slower than FrdaL2+/L- non-transfected cells, leading to 90% and 77% reduction of cell number, respectively, after 4 days in culture. In addition, both R2C1 and R2C2 grew slower than R2m clones (see below).

Figure 1
Depletion of frataxin in ribozyme clones. (A) Representative western blot analyses of protein extracts from different ribozymes clones revealed with polyclonal frataxin antibody is shown (five independent experiments were performed for quantitative analysis in B). Normalization was done using β-tubulin as a loading control. (B) Frataxin mRNA (white) and protein (grey) levels in antisense ribozyme fibroblast clones R2C1, R2C2, R5C1 and R5C2, compared to the FrdaL2+/L- non-transfected cell line. Three quantitative-RT-PCR analyses were performed on whole cellular RNA extracts, comparing frataxin expression to the reference Hprt gene. *p ≤ 0.05; ***p ≤ 0.005.
Frataxin deficiency in FRDA patients and in model organisms (mice, drosophila, and yeast) leads to a specific deficit in the ISC protein activities [23,30,54]. The enzymatic activities of mitochondrial respiratory chain succinate cytochrome c reductase (SCCR) and cytochrome c oxidase (COX), the tricarboxylic acid cycle enzymes aconitases (Aco), and isocitrate dehydrogenase (IDH) were measured spectrophotometrically in the frataxin-deficient clones compared to FrdaL2+/L- non-transfected cells. Interestingly, the two ISC enzymes (SCCR and Aco) showed a decreased activity in frataxin deficient clones (Fig. 3) with a SCCR/COX ratio of 1.56 ± 0.23 and an Aco/IDH ratio of 1.94 ± 0.16 in the frataxin deficient clones while the SCCR/COX and the Aco/IDH ratios were 1.97 ± 0.09 and 3.66 ± 0.34 in the control cells, respectively (Fig. 3). Moreover, the data parallel previous results from both FRDA patients and mouse models suggesting that the aconitases are more sensitive to frataxin deficiency than SCCR. Indeed, we found a 45% decrease in activity of aconitases with only a 19% decrease in SCCR activity in the ribozyme clones.

**Medium-scale pharmacological screen of the ribozyme cell model**

The proliferation delay of frataxin-deficient clones is an assay readout that is amenable to downscaling to 96-well plate format for easy automation. Set-up experiments were performed in order to select the best mutant cell line (R2C1 or R2C2), the seeding concentration (100 to 1,000 cells per well) and the time of culture before reading (3 or 4 days). Four different methods were tested to measure cell proliferation, based on nucleic acid detection (CyQUANT cell proliferation assay, Molecular Probe), ATP production (CellTiter-Glo Luminescent Cell Viability Assay, Promega) or reduction of tetrazolium salt (MTT test and CellTiter 96 AQueous Cell Proliferation Assay, Promega). The CellTiter-Glo assay showed the best results with a growth ratio (R2m control cells/R2C1 frataxin deficient cells) of 1.87 (corresponding to a 47% decrease growth rate for the frataxin-deficient clone) and the smallest standard deviation after 3 days. No major decantation effect or edge effect was detected. Due to contact inhibition of the cells occurring when confluence is reached into 96-well plates, the optimal time for output readings was 72 hrs after seeding.

Using the established screening conditions, the Prestwick Chemical Library, a collection of off-patent drugs and alkaloids, was screened to find candidate pharmacological compounds that could rescue the proliferation defect of the frataxin deficient cell line. The 1,120 molecules of the library were tested at a single concentration of 25 μM in 96-well format (Fig. 4A) using the CellTiter-Glo luminescent cell viability assay. We performed the screen on both frataxin deficient (R2C1) and control (R2m) cell lines. The Z’-factor classically used in evaluation and validation of HTS assays [55] cannot be evaluated in this screen as positive controls on cell growth were not available. The statistical analysis of luminescence intensity for frataxin-deficient (R2C1) and control (R2m) untreated cell lines during the primary screening showed a good growth ratio with small standard deviation (Fig. 4B). The coefficients of variation (CV) are within the acceptable range for a cell-based assay; i.e. below 10%. The control cell line proliferation rate was 2.10 ± 0.14 times higher when compared to the frataxin-deficient clone. Positive hits were designated for any compound with cellular growth increment over three standard deviations (increase in luminescence intensity as compared to untreated control wells of
Screening of the Prestwick Chemical Library. (A) Schematic representation of the three-step screening with hits yields. (B) Luminescence intensity of frataxin-deficient (R2C1) and control (R2m) untreated cell lines during the primary screening (14 plates for each cell line). Mean (M), standard deviation (SD), coefficient of variation (CV). (C) Effect of the 1,120 compounds of the library on the luminescence intensity in the control cell line R2m (upper panel) and in the frataxin-deficient clone R2C1 (lower panel) during the primary screening. Results are expressed as percentage of luminescence intensity compared to the same non treated cell line.
the same cell line). Eighty-seven primary hits were identified in the primary screening: fifty molecules increased proliferation rate in frataxin deficient cell line only, forty-six in the control cell line only and nine molecules had proliferative effect on both cell lines (Fig. 4C). All eighty-seven primary hits were tested for confirmation at two concentrations (2.5 and 25 μM) in duplicate, using the same hit selection criteria. Eighteen hits were retained with proliferative though minor effect, and were followed-up in a dose-response analysis. Each compound was tested at five concentrations (1, 3, 10, 30 and 100 μM) with four wells per concentration. However at this stage, no molecule presented a significant and reproducible strong effect on the proliferation rate of the frataxin deficient cell line (Fig. 4A).

Instability of the frataxin deficiency in the ribozyme cell lines

It is important to note that the R2C1 ribozyme cell line underwent numerous passages over a period of two years during the entire model set up and screening development. We therefore were interested in testing the stability of frataxin deficiency on different aliquots throughout the screening period. Despite the presence of the ribozyme (both at the genomic and RNA level, data not shown), Q-RT-PCR demonstrated that the frataxin mRNA level had increased by 1.8 fold (with a basal frataxin expression from 16 ± 5% to 29 ± 7% of wild type level). This "adjusted level" of frataxin deficiency was still associated with a deficit in the proliferation rate (by manual counting: 1.97 ratio at day 3 and 65% reduction of cell number at day 4), but the ISC protein activities (SCCR and aconitases) deficit was no longer present. The R2C1 cell line therefore became similar to FRDA patient's fibroblasts where no ISC enzyme deficiency can be found. However, Q-RT-PCR demonstrated that the "adjusted level" R2C1 cell line, in addition to the proliferation deficit, presented an increase of the Mthfd2 transcript (Fig. 5A), a transcriptional change associated with frataxin deficiency in mouse models [22] and FRDA fibroblasts (Fig. 5B).

Discussion

Cellular models are of great value for drug screening strategies and often represent an essential tool for both investigating molecular mechanisms of genetic diseases and identifying pharmacologically active compounds. We have used an antisense ribozyme strategy to establish a cell line with reduced frataxin level. Two clones presented a significant decrease in frataxin with a clear decrease in cell proliferation. Moreover, these frataxin deficient cells initially showed a deficit in the activity of two ISC enzymes (45% decrease in aconitase activity and 19% decrease in SCCR activity), a specific and characteristic feature of the human disease.

Our results on the ribozyme cell lines are in agreement with data observed in both transient and stable frataxin silencing models in HeLa cells obtained by RNAi strategies [45,47]. Upon frataxin depletion below ~20%, the three models display reduction of growth and decreased activity of the ISC proteins, specifically aconitases and succinate dehydrogenase. However, one notable difference is the altered morphology observed in the stable RNAi HeLa cell line, with roundish and grainy cells that easily detached from the plate [47]. This abnormal morphology is most likely due to the strongly reduced level of frataxin (almost undetectable) in the stable RNAi HeLa cell line, with roundish and grainy cells that easily detached from the plate [47]. This abnormal morphology is most likely due to the strongly reduced level of frataxin (almost undetectable) in the stable RNAi HeLa cell line, with roundish and grainy cells that easily detached from the plate [47]. This abnormal morphology is most likely due to the strongly reduced level of frataxin (almost undetectable) in the stable RNAi HeLa cell line, with roundish and grainy cells that easily detached from the plate [47]. This abnormal morphology is most likely due to the strongly reduced level of frataxin (almost undetectable) in the stable RNAi HeLa cell line, with roundish and grainy cells that easily detached from the plate [47]. This abnormal morphology is most likely due to the strongly reduced level of frataxin (almost undetectable) in the stable RNAi HeLa cell line, with roundish and grainy cells that easily detached from the plate [47].
sion and leads to cell death (unpublished results). These observations suggest that a threshold level of frataxin is necessary for cell proliferation and survival, consistent with the early embryonic lethality of the classical knockout mouse model [56].

While some candidate-based pharmacological compounds such as antioxidants ([36] for review) or iron chelators [37] have shown some promising results in clinical trial in providing protection on certain aspects of the disease, there is still no effective therapy for FRDA. Moreover clinical drug trials are difficult to organize for a disease like FRDA, due to the slowly progressive and chronic nature of the disease, the very large individual variations (due in part to the unstable expansion mutation), the low frequency of the disease, and the ethical issues raised by double-blind testing. Cellular models of the human disease short-cut all these problems, and should allow to obtain faster and more reliable results on efficacy of new compounds in pre-clinical trials. We have therefore used our frataxin-deficient cell line to perform a pharmacological robotized screening. Indeed, HTS has revealed to be a successful strategy for drug discovery, especially when rational design based on the knowledge of the molecular cause of the pathological dysfunction is unclear. To circumvent the limitations of screening large libraries, we have chosen to study a limited number of already available drug molecules, in accordance to the “selective optimization of side activities” (SOSA) approach [57]. Indeed, the Prestwick Chemical Library consists in 1,120 compounds that are structurally and therapeutically very diverse with known safety and bioavailability in humans. Despite the identification of 87 primary hits, 18 of which were confirmed at the secondary step, no molecule of the library has revealed a significant and reproducible positive effect on cell growth of the frataxin-deficient clone on a dose-response curve. This failure may be due to the rather aspecific assay readout chosen to follow the efficiency of the molecules. Indeed, cell proliferation is under the control of multiple regulatory pathways and could lead to high rate of false positive and negative results. The activities of ISC proteins would probably be a more suitable end-point for FRDA screening but these enzymatic measurements are not available for automated quantification.

A second explanation to this unproductive screen could be the rather low number of tested molecules. Knowing that such screening strategies retrieves between 0.1 and 1% of hits, it is statistically not surprising not to find a hit in a 1,120 compounds library. The screen of a larger compound library could allow to find active compounds. In spite of the absence of positive hit, this first cell-based automated screen on a FRDA cell model demonstrates the feasibility of the strategy.

The primary screen also identified one hundred and fifty one molecules decreasing ATP production in frataxin deficient and/or control cell lines. Two molecules specifically reduced the proliferation rate of the frataxin deficient clone. Although at first sight, the mecanism of action of both molecules (one expectorant and one vasodilatator) is hard to link to the current knowledge on frataxin, further investigation may uncover new pathways linked to frataxin.

Long term maintenance of the R2C1 frataxin-deficient clone has revealed a cellular adaptation to frataxin deficiency. Despite the persistence of the ribozyme construction, frataxin mRNA level has increased from 16 to 29% by an unknown compensatory mechanism, either by an increase in transcription or stability of the endogenous Fxn transcript, or by a reduction of the ribozyme efficiency. This slight increase in frataxin level was sufficient to restore normal ISC enzyme activities whereas proliferative deficit of the frataxin-deficient clone was still present. Furthermore, the Mthfd2 transcript, a mitochondrial enzyme involved in reduction of folate cofactors, was increased in the R2C1 clone, as previously observed at very early stages of pathogenesis in the cardiac mouse models [22] and also in FRDA fibroblasts (this manuscript). These data demonstrate the difficulty in obtaining stable cell line deficient in frataxin and could explain the paucity of long term stable models, necessary for pharmacological screening. As the long term persistence of frataxin deficiency was not tested in the stable RNAi model [47], we do not know if this adaptive mechanism is specific to our antisense strategy or is a more general feature characteristic of frataxin deficient cell lines.

Conclusion
The present work demonstrates the feasibility of a cell-based high-throughput screening assay in Friedreich ataxia but highlights the necessity of developing long-term robust cellular model that reproduce the physiopathology of the disease. Furthermore, the readout for the screen should be as specific as possible, in accordance to technical limitations.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
NCC carried out the characterization of the cellular model, participated in the pharmacological screening and drafted the manuscript. HS carried out the development of the cellular model and participated to the characterization. PV carried out the pharmacological screening. LR participated to the characterization of the cellular model. MH and JH conceived the screening strategy. PR carried out the biochemical analyses. MK and HP conceived the study, and participated in its design and coordination and drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgements

We thank J.L. Mandel and members of his laboratory for his discussions and comments. We thank C. Schumacher, C. Husser and A. Obrecht for technical assistance on the screening platform and J.L. Gali for discussion on the screening strategy.

This work was supported by funds from the GIS-Institut des Maladies Rares, the European Community (contract QLRT-CT-1999-00584), the Muscular Dystrophy Association of America (MDA), National Ataxia Foundation (NAF), INSERM, CNRS, and the Hôpitaux Universitaires de Strasbourg (HUS). H.S was supported by the Association Française contre l’ataxie de Friedreich (AFAF), the Association “Connaître les Syndrômes Cérébélueux” (CSC).

References

1. Durr A, Cossee M, Ayd G, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Koenig M: Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 1996; 335:1169-1175.

2. Harding AE: Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981, 104:589-620.

3. Campuzano V, Montermini L, Lutz Y, Hindelang C, Jiralerspong S, Trottier Y, Kish SJ, Faucheux B, Trouillas P, et al.: Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997, 6:1771-1780.

4. Cossee M, Campuzano V, Koutnikova H, Fischbeck K, Mandel JL, Koenig M, Bidichandani SI, Patel PI, Molte MD, Canizares J, et al.: Frataxin fracas. Nat Genet 1997, 15:337-338.

5. Grabczyk E, Mancuso M, Sammarco MC: A persistent RNA-DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 2007, 35:5351-5359.

6. Sakamoto N, Ohshima K, Montermini L, Pandolfo M, Wells RD: Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem 2001, 276:27171-27177.

7. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R, et al.: Oxidative stress enhances apoptosis in cells expressing variegated GAA*TTC repeats mediate heterochromatin formation. J Biol Chem 2003, 278:30132-30138.

8. Lamarche JB, Core M, Lemieux B: The cardiomyopathy of Friedreich’s ataxia morphological observations in 3 cases. Can J Neurol Sci 1980, 7:389-396.

9. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J: Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frat. Science 1997, 270:1709-1712.

10. Bradley JL, Homayoun S, Hart PE, Schapira AH, Cooper JM: Role of oxidative damage in Friedreich’s ataxia. Neurochem Res 2004, 29:561-567.

11. Emond M, Lepage Y, Vanasse M, Pandolfo M: Increased levels of plasma malondialdehyde in Friedreich’s ataxia. Neurology 2000, 55:1752-1753.

12. Piemonte F, Pastore A, Tozzi G, Tagliacozzi D, Santorelli FM, Carrozzo R, Cazali C, Damiano M, Federici G, Bertini E: Glutathione in blood of patients with Friedreich’s ataxia. Eur J Clin Invest 2001, 31:1007-1011.

13. Schultz JB, Dehmer T, Schols L, Mende H, Hardt C, Vorgerd M, Burk K, Matson W, Dychgans J, Beal MF, Bogdanov MB: Oxidative stress in patients with Friedreich ataxia. Neurology 2000, 55:179-182.

14. Chantrel-Grousard K, Geromel V, Puccio H, Koenig M, Munich A, Rustin A, Rustin P: Disabled early recruitment of antioxidant defenses in Friedreich’s ataxia. Hum Mol Genet 2001, 10:2061-2067.

15. Jiralerspong S, Ge B, Hudson TJ, Pandolfo M: Manganese superoxide dismutase induction by iron is impaired in Friedreich ataxia cells. FEBS Lett 2001, 509:101-105.

16. Santos MM, Ohshima K, Pandolfo M: Frataxin deficiency enhances apoptosis in cells differentiating into neuroectoderm. Hum Mol Genet 2001, 10:1935-1944.

17. Wong A, Yang J, Cavapini P, Gellera C, Londero B, Taroni F, Cortopassi G: The Friedreich’s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 1999, 8:425-430.

18. Sturm B, Bistrich U, Schranzhofer M, Sarcono JP, Rauen U, Scheiber-Mojdekar B, de Groot H, Ioannou P, Petrat F: Friedreich’s ataxia, new changes in mitochondrial labile iron in human lymphoblasts and fibroblasts: a decrease in antioxidative capacity? J Biol Chem 2005, 280:6701-6708.

19. Arnold P, Boulot Q, Mairre R, Kuntzer T: Expanding view of phenotype and oxidative stress in Friedreich’s ataxia patients with and without idebenone. Schweizer archiv für neurologie und psychiatre 2006, 4:169-176.

20. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH: Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 2009, 8:507-516.

21. Myers LM, Lynch DR, Farmer M, Friedman LS, Watson JA, Wilson RB: Urinary isoprostanes in Friedreich ataxia: Lack of correlation with disease features. Mov Disord 2008, 23(13):1920-2.

22. Seznec H, Simon D, Bouton C, Reutenauer L, Hertzog A, Gollik P, Procaccio V, Patel M, Draper JC, Koenig M, Puccio H: Friedreich’s ataxia: the oxidative stress paradox. Hum Mol Genet 2005, 14:463-474.

23. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, Koenig M: Mouse models for Friedreich’s ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001, 27:181-186.

24. Al-Mahdawi S, Pinto RM, Varshney D, Lawrence A, Lowrie MB, Hughes S, Webster Z, Blake J, Cooper JM, King R, Poole MA: GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neurologic and cardiac pathology. Genomics 2006, 88:580-590.

25. Lu C, Cortopassi G: Frataxin knockdown causes loss of cytoplasmic iron-sulfur cluster functions, redox alterations and induction of heme transcripts. Arch Biochem Biophys 2007, 457:111-122.

26. Seznec H, Simon D, Monassier L, Criqui-Filipe P, Gansmuller A, Rustin P, Koenig M, Puccio H: Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes defect in a mouse model for Friedreich ataxia. Hum Mol Genet 2004, 13:1017-1024.

27. Duby G, Fourny F, Ramazzotti A, Herrmann J, Lutz T: A non-essential function for yeast frataxin in iron-sulfur cluster assembly. EMBO Rep 2002, 3:271-277.

28. Martelli A, Wattenhofer-Donze M, Schmucker S, Bouvet S, Reutenauer L, Puccio H: Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet 2007, 16:2625-2635.

29. Muhlenhoff U, Richhardt N, Ristow M, Kispal G, Lill R: The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe-S proteins. Hum Mol Genet 2002, 11:2025-2036.

30. Rotig A, de Lonlay P, Chretien D, Fourny F, Koenig M, Sidi D, Munnich A, Rustin P: Aconitase and mitochondrial iron-sulfur protein deficiency in Friedreich ataxia. Nat Genet 1997, 17:215-217.

31. Fourny F, Pastore A, Trincal M: Acidic residues of yeast frataxin have an essential role in Fe-S cluster assembly. EMBO Rep 2007, 8:194-199.

32. Gerber J, Muhlenhoff U, Lill R: An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe-S cluster synthesis on Isu1. EMBO Rep 2003, 4:906-911.

33. Layer G, Ollagnier-de Choudens S, Sanakis Y, Fontecave M: Iron-sulfur cluster biosynthesis: characterization of Escherichia coli CaYa as an iron donor for the assembly of [2Fe-2S] clusters in the scaffold IscU. J Biol Chem 2006, 281:16256-16263.

34. Ramazzotti A, Vansmansart V, Fourny F: Mitochondrial functional interactions between frataxin and Isu1, the iron-sulfur cluster scaffold protein, in Saccharomyces cerevisiae. FEBS Lett 2004, 557:215-220.

35. Shany Y, Napoli E, Cortopassi G: Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum Mol Genet 2007, 16:929-941.
36. Pandolfo M. Drug Insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol 2008, 4:86-96.
37. Goddeeris NL, Le, Quan Sang KH, Rotig A, Leroy-Willig A, Gallet, S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
38. Richardson DR. Friedreich’s ataxia: iron chelators that target the mitochondrial iron as a therapeutic strategy? Expert Opin Invest Drugs 2003, 12:235-245.
39. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, Munnich A, Cabantchik ZI. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 2008, 112:5219-5227.
40. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Moidenberg H, Poewe-Moidenberg B. Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol 2007, 62:521-524.
41. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, Coppola G, Geschwind DH, Gottesfeld JM, Pandolfo M. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 2008, 3:e1958.
42. Jauslin ML, Wirth T, Meier T, Schoumacher J. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet 2002, 11:3055-3063.
43. Napoli E, Morin D, Bernhardt R, Buckpitt A, Cortopassi G. Hemin rescues adrenodinoxin, heme a and cytochrome oxidase activity in frataxin-deficient oligodendroglioma cells. Biochim Biophys Acta 2007, 1772:773-780.
44. Schoenfeld RA, Napoli E, Wong A, Zhan S, Reutenauer L, Morin D, Buckpitt AR, Taroni F, Lonnerdal B, Ristow M, et al. Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells. Hum Mol Genet 2003, 14:3787-3799.
45. Stelhing O, Elsasser HP, Bruckel B, Muhlenhoff U, Lill R. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum Mol Genet 2004, 13:3007-3015.
46. Tan G, Napoli E, Taroni F, Cortopassi G. Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 2003, 12:1699-1711.
47. Zanella I, Derosas M, Corrado M, Crevatin F, Biasiotti G, Poli M, Verardi R, Arosio P. The effects of frataxin silencing in HeLa cells are rescued by the expression of human mitochondrial ferritin. Biochim Biophys Acta 2008, 1782(2):90-8.
48. Kilpatrick MW, Phylactou LA, Godfrey M, Wu CH, Wu GY, Tsipouras P. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts. Hum Mol Genet 1996, 5:1939-1944.
49. Montgomery RA, Dietz HC. Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. Hum Mol Genet 1997, 6:519-525.
50. Feshern R. Culture of animal cells: a manual of basic technique 4th edition. Wiley-Liss Inc., New York; 2000.
51. Daya-Grosjean L, James MR, Drougard C, Sarasin A. An immortalized xeroderma pigmentosum, group C, cell line which replicates SV40 shuttle vectors. Mutat Res 1987, 183:185-196.
52. Metzger D, Chambon P. Site- and time-specific gene targeting in the mouse. Methods 2001, 24:71-80.
53. Rennst P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994, 228:35-51.
54. Anderson PR, Kirby K, Hilliker AJ, Phillips JP. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum Mol Genet 2005, 14:3397-3405.
55. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 1999, 4:67-73.
56. Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, LeMeur M, Fischbeck K, Dolle P, Koenig M. Inactivation of the Friedreich ataxia mouse gene leads to embryonic lethality without iron accumulation. Hum Mol Genet 2000, 9:1219-1226.
57. Wermuth CG. Selective optimization of side activities: the SOSA approach. Drug Discov Today 2006, 11:160-164.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/9/46/prepub